Informations sur le produit
MK-5204 is a novel antifungal agent that has been shown to have broad-spectrum activity in vitro and in vivo against various human fungal pathogens, including Aspergillus fumigatus. The compound is a carboxamide derivative with an isopropyl group at the C2 position and a triazole at the C3 position. It has been shown to be orally active against murine Candida albicans infection. The structural modifications are designed to increase solubility, reduce toxicity, and improve pharmacokinetics. MK-5204 has completed the first phase of clinical development and is currently undergoing optimization for oral administration.
MK-5204 is being developed by Merck Research Laboratories.
Propriétés chimiques
Question d’ordre technique sur : 3D-BM178545 MK-5204
Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages
